Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. - Wikidata - wikimedia - TriplyDB

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

http://www.wikidata.org/entity/Q37358879

about

Activation states of blood eosinophils in asthma New era of biologic therapeutics in atopic dermatitis Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis.Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy What targeting eosinophils has taught us about their role in diseases.Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome Novel targeted therapies for eosinophil-associated diseases and allergy Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Eosinophilic gastrointestinal diseases: review and update Advances in diagnosis and treatment of eosinophilia Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)Mepolizumab in eosinophilic disorders Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8 Eosinophils and disease pathogenesis Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.Novel targeted therapies for eosinophilic disorders Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.Mepolizumab.Allergy and eosinophil-associated gastrointestinal disorders (EGID).Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases.Biology of the eosinophil Biology and treatment of eosinophilic esophagitis.What's new in asthma pathophysiology and immunopathology?Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.Clinical management of the hypereosinophilic syndromes.Targeting eosinophils in allergy, inflammation and beyond.Eosinophilic Esophagitis: update on treatment approaches.Biological Modulators in Eosinophilic Diseases.Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.Eosinophilic Esophagitis and Gastroenteritis.Update on reslizumab for eosinophilic asthma.Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives.Mepolizumab in the treatment of severe eosinophilic asthma.Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.The clinical profile of benralizumab in the management of severe eosinophilic asthma.Benralizumab for the treatment of asthma.Eosinophilic esophagitis phenotypes: Ready for prime time?A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils.Impaired immune function in children and adults with Fanconi anemia.Diagnostic and therapeutic strategies for eosinophilic esophagitis.

P2860

Q26853383-3DD39607-DDC8-43FB-BF06-1A3F99F8AAC8 Q27001941-2A700ED8-1171-4B96-9225-6CCFFBD59794 Q33666772-CF6B6DFE-D154-4480-B524-D7DDC02A5E32 Q33692709-A11F847A-382C-4269-8E8E-4C539F353D32 Q33987218-D4BA251A-2B5B-4C0E-8DA2-1F81A407FEEB Q34176798-6D12D6BA-3E23-45B9-B125-44C4CEB876CD Q34444620-ECDE1603-BD63-4A90-9156-DD4DA6145D6B Q34544937-99BAF1E5-09DC-4B0B-B387-B33159BCA9C2 Q34640332-3FF10688-BCC9-43D2-8497-6A488FDF1C86 Q34895664-CF4DC619-E3F3-4578-A2A1-C538E14EC9F4 Q35041299-6738655A-AD21-4E6F-A382-12B4AB046759 Q35446671-142BC90F-5697-409D-BFB4-A4F93533C6F0 Q36139731-92F35EDB-BD65-4CA8-9CC6-6023AAEDCEAE Q36607847-48063B8A-15B7-4200-9453-69F9FE7FCBAC Q36654007-1ED737B0-D5BE-45AD-8C38-E6102B0951CA Q36763565-3C527419-3C75-44EB-AFD0-89A6F87705CB Q36859237-7AA01FF4-FB27-48DC-8C90-FBAF62A11078 Q36977252-A0A133C3-828B-4C74-A452-85C27207EF7D Q37249993-14148418-1CAB-42FF-9DBA-DADFE67E0D22 Q37336072-FC1F1C7D-07BE-40E5-889F-383C93BB85DD Q37397520-76C13109-F44C-4DC2-B5BA-43DB2A663657 Q37549336-0C198708-8E41-41B5-B104-AA6EAEDBCAC4 Q37798030-5F042813-99A6-4A9A-B90A-3DF4DA8F1884 Q37957225-19BEB650-6953-4AC1-95B1-398D0E1777D7 Q38025157-90E39F4D-29BA-469C-902E-46BEB76030BF Q38075409-2B06A70C-64E1-4CB3-956C-4EF2BF3AC8FE Q38128287-FF0F4D89-5691-4EA8-8FD1-0138DFBA1DB4 Q38240474-607E24C0-C8B5-4882-BA07-E19472E810F7 Q38314318-7CADCCCB-C02F-4DFD-940D-44ADAB7FDBB9 Q38558964-B566B6A0-1982-4735-A38D-113F1DCCE012 Q38587334-CB7C6799-8428-4533-9066-4AEB0C1CDA77 Q38613170-62ED1C55-D0C5-41C8-B2AD-2F4CF53DA7C7 Q38664948-E4D11994-1B63-4066-9932-0F7BCCC50E47 Q38818964-34B1E1A6-CE60-4217-87C9-13DF9AF1FFB4 Q38822826-366CC038-0B59-4EF9-A6CE-F86089523ED5 Q38853525-C9F3283B-3AA6-461E-A2EE-181E86539096 Q39198682-9F6B7D4D-D6E5-4634-BFF9-D0C91E38DE93 Q40067123-E703A067-A383-46EE-8542-63E6C00BB5D7 Q40180973-08809848-3E7D-469F-87FD-2BA1FEAE1677 Q41882445-12DD3DCD-D9BB-4D4E-A366-0CFC5C04FDF7

P2860

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

http://www.wikidata.org/entity/Q37358879

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-IL-5 (mepolizumab) therap ...... IL-5 and IL-5 receptor levels.

@en

Anti-IL-5

@nl

type

label

Anti-IL-5 (mepolizumab) therap ...... IL-5 and IL-5 receptor levels.

@en

Anti-IL-5

@nl

prefLabel

Anti-IL-5 (mepolizumab) therap ...... IL-5 and IL-5 receptor levels.

@en

Anti-IL-5

@nl

P1433

Q37358879-3D85F442-85E5-45AA-9F0F-C903F2F2728C

P1476

Q37358879-365F9E5D-9B11-47F2-BB9E-04001248C091

P2093

Q37358879-19E51686-201C-4F8D-9B58-D2BC28CC186F

Q37358879-239FF542-7B06-4281-BC97-DA5CE71CC7DD

Q37358879-4D1E5EC3-688A-4B72-A49B-92869A7223A0

Q37358879-656FEA20-B628-45F6-9FAB-86FB03F06EC1

Q37358879-86DE19A8-4ACF-4089-B7C2-953789941F03

Q37358879-C9ECCD3D-7247-49B9-91A7-6CE62F424255

Q37358879-F8C03238-88E8-4F79-AEA4-20C1C034ED87

P2860

Q37358879-015BFEC0-FD5F-4ECE-8DAA-CB5C9D10F38F

Q37358879-0737EB51-9446-45A7-8350-1EDEF0F1188A

Q37358879-0B80BC3C-D249-4B03-B715-12567BF907AA

Q37358879-14141859-B7B5-4963-98A1-6C30F1E8E27B

Q37358879-22387A72-DEE1-44EB-8648-B3832E7C721E

Q37358879-3AA2858C-9CA3-4C0C-8926-6D2BB9F4985C

Q37358879-3AC200E7-C75B-406E-8636-7DBB988272E9

Q37358879-4161CF7D-238A-42A0-B7AD-453CC55965BD

Q37358879-4F11B3E0-0D1E-4E6E-9563-5628DC5D3BA4

Q37358879-5B556493-CF4F-45F3-9E5E-846AF822C7AF

P304

Q37358879-3BCBC01B-8199-4559-BF98-32A5EA8A32FC

P31

Q37358879-1FA8A66D-1792-41B8-9277-797A4CF15E6D

P356

Q37358879-C3FC40DC-81DF-4C58-9391-3A9BD3760CDC

P407

Q37358879-1FC9C2CB-5A62-4EC6-97E0-0B5C0BC1D6BE

P433

Q37358879-01DA187E-72E1-4931-9BFF-B92774F9AC4D

P478

Q37358879-A51A5765-4DC7-4F6A-815C-C6BA25A02CBD

P577

Q37358879-8A21DAE8-B10F-46D6-9CF8-9264DC44A507

P5875

Q37358879-BBAB6649-2552-416C-A086-DE8DF52411EE

P698

Q37358879-CA9F1856-7F99-445F-B3D7-C19366ED9947

P921

Q37358879-FB8BFBB8-285E-4F2C-B257-69DB8DA297D6

P932

Q37358879-D7D09A78-7DF4-433A-A7BF-AC31E9DFA9B3

P356

J.JACI.2008.02.033

P1433

The Journal of Allergy and Clinical Immunology

P1476

Anti-IL-5 (mepolizumab) therap ...... IL-5 and IL-5 receptor levels.

@en

P2093

Alexandra H Filipovich

http://www.w3.org/2001/XMLSchema#string

Amal H Assa'ad

http://www.w3.org/2001/XMLSchema#string

Bridget K Buckmeier

http://www.w3.org/2001/XMLSchema#string

Joyce M Villanueva

http://www.w3.org/2001/XMLSchema#string

Marc E Rothenberg

http://www.w3.org/2001/XMLSchema#string

Miguel L Stein

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways

An etiological role for aeroallergens and eosinophils in experimental esophagitis

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit

Interleukin-5, eosinophils, and disease

The eosinophil.

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Eosinophilic gastrointestinal disorders (EGID).

Schistosoma mansoni infection in eosinophil lineage-ablated mice.

P304

1473-83, 1483.e1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2008.02.033

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5441646

http://www.w3.org/2001/XMLSchema#string

P698

18410960

http://www.w3.org/2001/XMLSchema#string

P921

P932

2749495

http://www.w3.org/2001/XMLSchema#string